Market Intelligence, Clinical Progress, and High-Purity Reagents for Myeloid Neoplasms and Solid Tumor Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for U2AF1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | U2AF1 (S34F / Q157R) Mutant & WT Recombinant Proteins High purity (>95%), Endotoxin controlled. Sequence Verified. |
View U2AF1 Products |
| Gene Delivery | U2AF1 WT / S34F Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and splicing reporter assays. |
View U2AF1 Products |
| Benchmark Ab | Anti-U2AF1 Recombinant Antibody Recombinant positive control for Western Blot and IP. |
View U2AF1 Products |
| Validator | U2AF1 siRNA Set For knockdown verification and synthetic lethality screening validation. |
View U2AF1 Products |
| Related Target A | SF3B1 Core spliceosome component; frequently co-mutated or mutually exclusive in MDS/AML. |
View SF3B1 Products |
| Related Target B | SRSF2 Splicing factor driver mutation target; essential for RNA splicing pathway screening. |
View SRSF2 Products |
| Related Target C | U2AF2 U2AF 65 kDa subunit; heterodimerizes with U2AF1 to facilitate 3' splice site recognition. |
View U2AF2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| S34F/Q157R Mutant-Selective Binding | Mutant vs WT recombinant proteins sequence-verified and purity-checked via SDS-PAGE (>95%) |
| RNA-Binding Domain Stability | E. coli or Insect cell-expressed constructs optimized for zinc-finger domain stability |
| Lack of Controls | High-affinity Recombinant Positive Control Antibodies included |
| False Positives | Validated siRNA sets included for functional splicing rescue and knockdown assays |
Live U2AF1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for U2AF1 therapeutics is intensifying, with major players shifting focus from traditional global spliceosome inhibition to mutant-selective small molecules and synthetic lethality strategies. As first-generation splicing modulators reach the clinic, the next wave of R&D is targeting the vulnerable dependency of U2AF1-mutant cells on wild-type splicing machinery and downstream pathways such as PRMT5 or IRAK4.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Splicing Modulator) | Eisai (H3 Biomedicine), Loxo Oncology | MDS, AML, NSCLC | Selectivity Assay (Need Mutant vs WT Proteins) |
| Synthetic Lethality (PRMT5/IRAK4 Inhibitors) | Prelude Therapeutics, Ryvu Therapeutics | Spliceosome-mutated Hematological Malignancies | Pathway Validation (Need S34F Lentivirus for stable line generation) |
| Antisense Oligonucleotides (ASO) | Academic Institutes, Biotech Startups | U2AF1-mutant cancers | Splicing correction validation (Need validated siRNA and ORF constructs) |